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• Lynn Osako, Pharm.D, 
Goal 
Mary Gutierrez, Pharm.D. and 
Michael Wincor, Pharm.D. 
Update on 
anxiolytics and 
hypnotics 
The goal of this article is to educate pharmacists on the new er anxiolytic 
and hypnotic agents. 
Objectives 
After reading this article, the pharmacist shouid be able to: 
• Discuss the advantages of the new hypnotics and anxiolytics over 
previous agents. 
• Discuss possible adverse effects and drug interactions of the new 
hypnotics and anxiolytics. 
• Recommend one of the newer agents as an alternative to more conven-
tionai therapy when appropriate. 
Provided by an educational grant from 
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History 
Agents to produce sleep, called 
hypnotics, have been around thousands 
of yeats. Evidence shows that poppy 
plants were used as the first hypnotics 
sorne two-thousand yeats ago. The old-
est hypnotic agent is chloral hydrate. Its 
popularity waned when the barbiturates 
came along but has become more popu-
lar in the last few decades. 1 It is less 
effective than flurazepam and tolerance 
toits effects develops rapidly.2 
The bromides were introduced in the 
mid-1800s. Problems with these agents 
include the ir extremely long half-life of 
about 12 days, their low therapeutic in-
dex and irritation to the Gl system.1 
Early in the 20th century, barbitu-
rates were introduced and quickly be-
came popular hypnotic agents. These 
agents have numerous adverse reactions 
such as respiratory depression, nausea 
and vomiting, circulatory collapse and 
severe depression of the CNS. Barbitu-
rates have become associa red with abuse 
and overdose, and drug withdrawal can 
also be a serious problem. A chronic user 
of barbiturates, upon withdrawal, may 
experience irritability, insomnia and, in 
serious cases, convulsions and death. 1 
Other nonbarbiturate-nonbenzo-
diazepines indu de piperidinediones su ch 
as glutethimide and methyprylon, 
ethchlorvynol, methaqualone and mep-
robamate. Ali of these agents have prob-
lems similar to th ose of the barbiturates, 
specifically physical dependence and 
overdose potential. 1 •3 
Benzodiazepines were a major break-
through in sedative-hypnotics and have 
become the most frequently prescribed 
drugs in the U.S. Their main advantage 
over previous agents are their higher 
therapeutic index. T aken alone, these 
agents rarely cause death and produce 
little respiratory depression. 1•3 Physical 
dependence has become their major 
problem, however. 1 
Drug therapies of anxiety states are a 
"' 
1 
fairly recent development. Although 
anxiety states were recognized in the 
19th cenrury, most therapy revolved 
around psychotherapy.4 A variety of 
drugs in different pharmacological classes 
are now used to treat the anxiety disor-
ders. Alcohol is commonly used to self-
rreat situational anxiety; however, it is 
never a treatment of choice, 5 and alco-
holism has become a complication of 
many anxiety disorders. z 
When barbiturates came along, they 
were not only used as hypnotics, but also 
used to treat anxiety.2 Barbiturates are 
not, however, specifie anxiolytics and 
have the disadvantages discussed ear-
Her. 
Antihistamines are used occasionally 
and are especially good for patients with 
a high propensity for drug abuse.5•6 The 
anticholinergic effects of these agents 
are their primary disadvantage, espe· 
cîally in the elderly in whom central 
effects such as confusion and hallucina-
tions may also occur.5 
Beta-adrenergic blocking agents are 
used primarily to alleviate the physical 
symptoms of stress. These agents are 
nonspecific and rarely are helpful in 
psychiatrie patients.4 Clonidine is also 
used to treat anxiety; however, its side 
effects of hypotension, depression and 
fatigue have limited its use.5 
Antipsychotics were used more fre-
quently for anxiety attacks in the past. 
They are less commonly used for thar 
purpose now because of their question-
able efficacy and the ir high potential for 
adverse effects su ch as tardive dyskinesia 
and extrapyramidal effects. 4•6 
Antidepressants, however, continue 
to be used and have shawn efficacy in 
certain anxiety states. In the early 1960s 
monamine oxidase inhibitors (MAOls) 
were found to be effective for panic 
disorder.6 Phenelzine is most commonly 
used, and studies have proven its effec-
tiveness in panic disorder.5 Side effects 
include orthostatic hypotension, weight 
gain, sexual dysfunction, edema and 
hypertensive crisis, which can occur 
when the patient on an MAOI eats food 
rich in tyramine (aged cheese, red wine, 
sherry, beer, smoked meats orfish, etc.) 
and uses sympathomimetics or stimu-
lants. Another disadvantage is that it 
takes weeks for a noticeable effect to 
occur.5 
lmipramine is the tricyclic amide-
pressant (TCA) most commonly used 
for treating panic disorder, while other 
TC As su ch as desipramine are occasion-
ally used.5 Like the MAOis, weeks of 
therapy are required before a response 
occurs. Their anticholinergic side ef-
fects are more pronounced than with the 
MAOls and may cause psychotic reac-
tions, especially in the elderly.2•5 TCAs 
can also cause orthostatic hypotension, 
tachycardia and decreased cardiac con-
duction. 2•5 T oxicity is another serious 
problem with these patients, and a few 
week's supply can easily cause death. 
Benzodiazepines, as mentioned car-
lier, are the most commonly prescribed 
drugs in the U.S. Anxiery syndromes 
make up a large percentage of those 
prescriptions, and benzodiazepines can 
be used in ali different types of anxiety 
disorders. Their advantages and disad-
vantages are mentioned above in the 
discussion on hypnotics. 
The need for newer agents 
Although the above-mentioned 
agents are effective against anxiety and 
insomnia, each has its own problems. 
The major disadvantage for all the 
hypnotics and for most of the anxiolytics 
is their potential for physical depen-
dence. For those anxiolytics without 
addictive potential, the primary prob-
lems are adverse effects and toxicity. 
Therefore, the search goes on for drugs 
with specifie actions, few side effects, a 
high therapeutic index and no addictive 
potential. 
Buspirone (Buspar®) 
Buspirone is a relatively new drug 
which is unique from the beruodiaz-
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epines in itschemical and pharmacologie 
properties. It was first introduced in 1985 
in West Germany and is the first drug 
developed primarily as an anxiolytic.4 
Pharmacology. Unlike the benzodi-
azepines, buspirone actually increases 
noradrenergic activity. Buspirone's 
mechanism of action is not completely 
understood, but it apparently does not 
involve action on the benzodiazepine-
gamma aminobutyric acid-chloride ( BZ-
GABA-Cl) ionophore camp lex. It binds 
selectively ta 5-HT lA receptors, and this 
is most likely where the majority of its 
• 
The major 
disadvantage for ali 
the hypnotics and for 
most of the anxiolytics 
is their potential for 
physical dependence. 
For those anxiolytics 
without addictive 
potential, the primary 
problems are adverse 
effects and toxicity. 
anxiolytic activity is produced. 7 These 
receptors are localized in areas of the 
CNS which may explain its more favor-
able adverse effect profile versus the 
benzodiazepines. Buspirone does not 
share the anticonvulsant and muscle 
relaxant properties of the benzodiaz-
epines and exhibits anxiolytic effects 
only.7 
Pharmacokinetics. Buspirone is ab-
sorbed rapidly and completely from the 
01 system. After undergoing first-pass 
metabolism only 4% of the drug reaches 
the systemic circulation.5 The onset of 
action of buspirone is considerably de-
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layed and occurs sometime during the 
first three weeks of therapy; therefore, it 
cannat be used for short-term or as-
needed treatment. The distribution of 
buspirone is not completely known. The 
apparent volume of distribution is about 
5.3 L/kgJ It is 95% bound to plasma 
proteins,5 mostly to albumin and a 1-
acid glycoprotein. The elimination half-
life is about four hours in healthy pa-
tients while it is prolonged with renal 
impairment and hepatic cirrhosis. 
Buspirone is metabolized in the liver, 
primarily by oxidation, into several me-
tabolites. The major active metabolite is 
1-pyrimidinyl-piperazine (1-PP). lt has 
about 20-25% of the anxiolytic activity 
ofbuspirone; 7 however, it is unclear how 
much it adds to buspirone's action. Both 
buspirone and its metabolites are ex-
creted primarily in the urine although 
less than 0.1% is excreted as unchanged 
drug.7 
Adverse effects. Adverse effects 
which have been reported include gas-
trointestinal complaints (nausea and 
vomi ting), dizziness and headache. Each 
of rhese si de effects were reported in less 
than 10% of patients. Sedation is re-
ported in 10% of patients, which is the 
same incidence as with placebo. There 
are slightly more reports of adverse ef-
fects in the elderly.4 Also, there are few 
reports of psychomotor impairment. 
Another unique feature of buspirone is 
its inability to potentiate the effect of 
alcohol and lack of addiction potential. 4 
There is little information on the 
toxicity ofbuspirone. Because dysphoria 
may occur at higher doses of 20-40 mg, 7 
there is low potential for abuse. There 
also is little evidence rhat withdrawal 
occurs with sudden discontinuation of 
the drug. For acute roxicity, there are no 
specifie antidotes and treatment usually 
involvessupportive care. The lethal dose 
in humans is unknown.4 
Drug interactions. Drug interactions 
include elevated blood pressure in pa-
tients with concurrent MAOI use. 
Therefore, ir is not recommended to 
give both concomitantly, and there 
should be a 1 0-day washout after MA 01 
use before buspirone therapy is initi-
ated. 8 The re have be en reports of eleva-
tions in ALT concentrations with con-
comitant buspirone and trazodone use. 
However, this remains unconfirmed in 
studies. As long as liver function tests 
are monitored, the manufacturer daims 
thar the two may be used together.8 
When haloperidol and buspirone are 
used together, elevations occur in 
haloperidol concentration. This prob-
ably occurs through competition resulr-
ing in the inhibition of the metabolism 
of haloperidol.8 lt is not recommended 
that both be used concurrently until 
more information is obtained on this 
interaction. 8 Buspirone does not appear 
to interact with benzodiazepines; how-
ever, it is still recommended that they 
not be given together.8 
Indications. Indications for buspirone 
include generalized anxiety disorders. 
• The side effect profile 
of buspirone is a 
definite advantage 
overthe 
benzodiazepines. 
There is little 
sedation, making it 
an alternative for 
patients in whom the 
sedation and 
psychomotor 
impairment are 
intolerable. 
Studies have shown that buspirone is as 
effective as benzodiazepines for these 
disorders.8 In severe anxiety, however, 
buspirone is lesseffective than lorazepam 
and diazepam. 5 Previous treatment with 
benzodiazepines is often associated with 
disappointment in buspirone therapy. s, 7 
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This is probably due to its long onset of 
action and because buspirone does not 
alleviate the withdrawal symptoms of 
benzodiazepines. 
Dosing and administration. 
Buspirone is only available orally. The 
starting dose is 10-15 mg/cl in two or 
three divided doses. lt can be given with 
or without food. Increases of 5 mg/day 
every two to four da ys can be made after 
one week of therapy at 15 mg/day. The 
usual maximum dose is 60 mg/day. Op-
timal effects may not occur for as long as 
six weeks. 5 It has not been determined 
how to ad just doses in hepatic and renal 
impairment. Sorne have suggested a 25-
50% reduction in patients thatare anurie. 
The side effect profile ofbuspirone is 
a defini te advantage over the benzodiaz-
epines. There îs little sedation, making 
it an alternative for patients in whom 
the sedation and psychomotor impair-
ment are intolerable. lt would also be 
indicated in patients who may have a 
history of drug dependence. The disad-
vantage is its long onset of action. ln 
patients with symptoms requiring im-
mediate alleviation, buspirone may not 
be ideaL 
Clomipramine (Anafranil®) 
Clomipramine is a tricyclic antide-
pressant used for more than 20 years in 
Europe and Canada which has more 
recently been used for various anxiety 
disorders. 9 lt is so far the only agent 
approved for obsessive-compulsive dis-
arder ( OCD) and is marketed in the 
U.S. for this indication. 
Pharmacology. Clomipramine inhib-
its reuptake of serotonin and norepi-
nephrine like the other tricyclic amide-
pressants and is the most potent seroto-
nin reuptake blocker in its class.10 The 
activity of clomipramine is thought to 
be due toits inhibitory effect on seroto-
nin. This activity increases serotonin 
levels, and long-term treatment may lead 
to a clown regulation of the serotonin 
receptors. However, its exact mecha-
nism is unknown.9•10 
Pharmacokinetics. Absorption is 
rapid and complete from the Gl system, 
but the drug undergoes first pass effect. 
Systemic bioavailability is about 50%.11 
The distribution pattern has yet to be 
completely determined. The mean ap-
parent volume of distribution is 
12 L/kg. 11 lt is 98% protein bound to 
plasma proteins.9·11 Clomipramine isex-
tensively metabolized to a variety of 
metabolites. Demethylclomipramine, 
the major metabolite and a result of first 
pass demethylation, is active. Approxi-
mately 50-60% of the oral dose is found 
in the urine and the rest is in the feces. 
The mean elimination half-life of 
clomipramine is 32 hours while 
demethylclomipramine's mean half-life 
is 69 hoursP 
Adverse effects. Clomipramine has 
the same adverse effect profile as the 
other tricyclic antidepressants.9 The 
anticholinergic effects are most promi-
nent and include dry mouth, constipa-
tion, sweating, blurred vision and uri-
nary retention.9 Cardiac effects include 
orthostatic hypotension, syncope, pal-
pitations and tachycardia. 9 Seizures have 
been reported at an incidence of 0.7% 
and were more common with high doses 
( > 300 mg/day) and with intravenous 
administration.9 One particularly dis-
turbing problem to patients is sexual 
dysfunction, although normal function 
retums withdiscontinuation of the drug.9 
Weight gain can also be a problemY lt is 
essential to counsel patients about these 
two side effects. ln sorne trials there is a 
dropout rate of up to 28%.9 
Acute toxicity with clomipramine is 
similar to those of other tricyclic amide-
pressants. Symptoms include severe an-
ticholinergic effects. ln extreme cases, 
hypotension, coma, cardiac abnormali-
ties, convulsions and respiratory arrest 
may occur. T rearment involves the usual 
JOURNAL CE 
treatment of triey clic antidepressant tox-
icity. The guidelines can change; there-
fore, a poison center should be ca lied for 
updated information. 12 
Indications. Clomipramine, unlike 
most of the other tricyclic antidepres-
sants, is used to treat obsessive compul-
sive disorder and panic disorder. Early 
studies have shown thar clomipramine 
is superior to other tricyclic antidepres-
sants in treating OCD.9•10 
Dosing and administration. The start-
ing dose for domipramine in OCD is 25 
mg two to three times daily. 10 The dose 
should be increased slowly depending 
on response and tolerance of side effects, 
up to 100-150 mg, although 250 mg has 
been used. Drug effect can take as long as 
five to six weeks to manifestY Once 
symptoms have been alleviated the dose 
should be brought down to the lowest 
effective level. 
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Quazepam (Dorai@) 
Quazepam is a benzodiazepine intro-
duced in 1990. The action of quazepam, 
like other benzodiazepines, revolves 
around its actions on GA BA. Quazepam 
and one of its metabolites, 2-
oxoquazepam ( OQ), have selectivity for 
type 1 benzodiazepine receptors. 13 This 
is a unique quality which is shared by 
only one ether benzodiazepine, 
halazepam. The significance of this se-
lectivity is yet to be elucidated.14 
Phannaeokinetics. Quazepam is ab-
sorbed rapidly and its bioavailability is 
approxima tel y 80%.8 There is, however, 
extensive first pass metabolism in ani-
mals which has not been quantified in 
humans. Quazepam is distributed into 
most tissues and body fluids, and the 
apparent volume of distribution is 5 L/kg 
when given at bedtime and 8.6 L/kg 
when given in the moming. 14 Both 
quazepam and OQ distribute quickly 
into the CNS and are more than 95% 
bound to plasma proteins.13 Quazepam 
is extensivelymetabolized toOQ and N-
desalkyl-2-oxoquazepam (DOQ), which 
is identical to N-desalkylflurazepam. 
Both metabolites have similar activity 
to the parent drug. The half-life of 
quazepam and OQ is about 40 hours.U' 14 
The half-life of DOQ is about 70-75 
hours.13 In the elderly, the most signifi-
cantchange in half-life is in DOQ, which 
can increase to 190 hours.l4 Both me-
tabolites are metabolized ultimately via 
conjugation with glucuronide formation. 
Quazepam is excreted both in urine and 
feces with very little in its original form. 
Adverse effects. Adverse effects of 
quazepam are similar to other benzodiaz-
epines. These indude CNS depression 
and physical dependence. Quazepam 
may cause more daytime sedation than 
other benzodiazepines with shorter half-
lifes. Sedation is also more of a problem 
at the higher dose of 30 mg.13 Side ef-
fects are usuaU y most pronounced in the 
first few days and may diminish with 
ti me or with decreases in dosage. At one 
week and four weeks of therapy, there 
appears to be little daytime drowsiness.15 
There have been rare reports of confu-
sion and psychotic-like symptoms at the 
30 mg dose, but none are reported at the 
15 mg dose. 14 Rebound insomnia is not 
a problem with quazepam due to the 
long half-life ofDOQ.D With respect to 
• 
When compared with 
temazepam, 
quazepam appears to 
be more effective 
with short-term use, 
and there also seems 
to be less tolerance 
development when 
quazepam is used 
longer term. 
dependence, quazepam appears to have 
a low potential for abuse due to its 
carryover effects and decreased incidence 
ofrebound insomnia. No definitive state-
ments can be made though untillarger 
numbers of patients use this drug and 
more studies are done.14 
Drug interactions. Drug interactions 
include additive CNS effects with other 
CNS depressants, anticonvulsants and 
alcohol. If drugs from both classes need 
to be used together, reductions in doses 
will be required to prevent overdosage. 
Administration of disulfiram and benzo-
diazepines which undergo oxidative 
merabolism may result in a decreased 
metabolism of the benzodiazepine.8 
Sin ce quazepam is one of the these agents, 
patients taking both these agents should 
be watched for a greater response to 
quazepam. This is also the case with 
concomitant cimetidine administration. 
Cimetidine may inhibit the clearance of 
quazepam; therefore, response must again 
be monitored and dosage reductions 
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made as necessary.8 
Indications. Quazepam is used pri-
marily as a hypnotic. lt shares a similar 
pharmacokinetic profile as flurazepam 
and is very comparable in terms of effi-
cacy and side effect profile. Flurazepam 
may have better long-term effective-
ness, however.14 When compared with 
temazepam, quazepam appears to be more 
effective with short-term use, and there 
also seems to be less tolerance develop-
ment when quazepam is used longer 
term. 13•14 
Dosing and administration. 
Quazepam is available in oral form and 
given only a bedtime. The starting dose 
is 15 mg in most adults. ln sorne people, 
7.5 mg may be enough. The higher dose 
of 30 mg is sometimes used, but there is 
generally more daytime sedation at that 
dose. Quazepam and flurazepam share 
the same active metabolite and will 
therefore share many of the same prop-
erties. Quazepam may have advantages 
over temazepam and triazolam, but seerns 
to have little over flurazepam. 
Estazolam (ProSom®) 
lntroduced in 1991, Estazolam is an-
other new benzodiazepine. 
Pharmacology. Like other benzodi-
azepines, estazolam's actions are due to 
its effects on GABA. It is unknown 
whether estazolam has selectivity for 
either benzodiazepine type 1 or 2 recep-
tors. 
Pharmacokinetics. Estazolam is both 
rapidly and well-absorbed from the GI 
tract. The bioavailability is approxi-
mately 98%. It distributes widely into 
most tissues and fluids, and it appears to 
cross the blood-brain barrier.8 The half-
life ranges from 8-31 hours. 2 Estazolam is 
metabolized hepatically, and its metabo-
lites have little activity. The two princi-
pal ones are 4-hydroxyestazolam and 1-
oxo-estazolam. Both estazolam and its 
metabolites are primarily excreted in 
urine with a small percent excreted in 
feces. 
' ; 
Adverse effects. The side effect pro-
file is essentially the same as that for 
quazepam, as is the drug interaction pro-
file. In a study looking at long-term 
administration, no tolerance was seen 
during the six weeks of therapy.16 The 
same study showed that rebound insom-
nia could occur with sudden withdrawal, 
but that this was just temporary. 16 
Drug interactions. Estazolam is oxi-
datively metabolized; therefore, there is 
again the potential for its increased ac-
tivity when given with cimetidine or 
disulfiram. Doses should be adjusted 
when given concomitantly with these 
agents. 
Indications. Estazolam is used, as are 
other benzodiazepines, as a hypnotic. 
Estazolam has an intermediate half-life 
which makes it less likely to cause day-
time sedation than th ose with long half-
lives. It is also less likely to cause the 
rebound insomnia seen when discon-
tinuing benzodiazepines with short ha If-
lives. Early studies show that estazolam 
has fewer side effects than flurazepam 
and is equally efficacious as a hypnotic. 17 
Dosing and administration. 
Estazolam is available in oral form only. 
The starting dose of estazolam in adults 
is 1 mg at bedtime. The dose th en may be 
slowly increased to 2 mg. In elderly pa-
tiems, the dose should be started at 
0.5 mg at bedtime. Wh en patients have 
been on therapy for long periods, they 
should be tapered slowly to avoid with-
drawal. Estazolam has an intermediate 
half-life and would be expected to be 
similar to other benzodiazepines with 
similar half-lives such as temazepam. 
This agent is not expected to have any 
obvious advantages. Estazolam has only 
been available for a year. Until there is 
more widespread use of the drug, we will 
not know if there are any clear advan-
tages or disadvantages. 
Conclusion 
Although new anxiol ytics and 
hypnotics continue to appear on the 
market, very few of them have any sig-
nificant advantage over previous agents. 
Buspirone appears to be a breakthrough 
in rhat it is significantly different from 
previous agents. It has specifie effects, 
low incidence of side effects and little, if 
any, addiction potential. However, its 
long onset of action is a disadvantage. 
Clomipramine also has sorne advantages 
in that it has increased efficacy over 
imipramine in the treatment of OCD; 
however, it has many of the same side 
effects. The two newer benzodiazepines 
appear to have little advantage over the 
older agents. Perhaps with continued 
use, more advantages and/or disadvan-
tages will be revealed. It appears that the 
search for the perfect anxiolytic and 
hypnotic will have to continue. 
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